Expression and/or activity of the SVCT2 ascorbate transporter may be decreased in many aggressive cancers, suggesting potential utility for sodium bicarbonate and dehydroascorbic acid in cancer therapy

Medical Hypotheses

Volumn 81, Issue 4, 2013, Pages 664-670

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BICARBONATE; DEHYDROASCORBIC ACID; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SVCT2 ASCORBATE TRANSPORTER; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL; CANCER THERAPY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; METASTASIS; TUMOR INVASION;

MUS MUSCULUS; RODENTIA;

DEHYDROASCORBIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; SODIUM BICARBONATE; SODIUM-COUPLED VITAMIN C TRANSPORTERS;

EID: 84883787092     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.07.023     Document Type: Article

References (95)

1. Blagosklonny M.V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol 2001, 19(2):257-262.
2. Powis G., Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004, 3(5):647-654.
3. Robey I.F., Lien A.D., Welsh S.J., Baggett B.K., Gillies R.J. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005, 7(4):324-330.
4. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62(12):3387-3394.
5. Patiar S., Harris A.L. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 2006, 13(Suppl. 1):S61-S75.
6. McCarty M.F., Barroso-Aranda J., Contreras F. Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses 2010, 74(5):789-797.
7. Semenza G.L. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008, 60(9):591-597.
8. Masson N., Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci 2003, 116(Pt. 15):3041-3049.
9. Lando D., Gorman J.J., Whitelaw M.L., Peet D.J. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem 2003, 270(5):781-790.
10. Bruegge K., Jelkmann W., Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 2007, 14(17):1853-1862.
11. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002, 16(12):1466-1471.
12. de J.L., Albracht S.P., Kemp A. Prolyl 4-hydroxylase activity in relation to the oxidation state of enzyme-bound iron. The role of ascorbate in peptidyl proline hydroxylation. Biochim Biophys Acta 1982, 704(2):326-332.
13. Kaczmarek M., Cachau R.E., Topol I.A., Kasprzak K.S., Ghio A., Salnikow K. Metal ions-stimulated iron oxidation in hydroxylases facilitates stabilization of HIF-1 alpha protein. Toxicol Sci 2009, 107(2):394-403.
14. Karaczyn A., Ivanov S., Reynolds M., Zhitkovich A., Kasprzak K.S., Salnikow K. Ascorbate depletion mediates up-regulation of hypoxia-associated proteins by cell density and nickel. J Cell Biochem 2006, 97(5):1025-1035.
15. Vissers M.C., Gunningham S.P., Morrison M.J., Dachs G.U., Currie M.J. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radical Biol Med 2007, 42(6):765-772.
16. Page E.L., Chan D.A., Giaccia A.J., Levine M., Richard D.E. Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008, 19(1):86-94.
17. Flashman E., Davies S.L., Yeoh K.K., Schofield C.J. Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents. Biochem J 2010, 427(1):135-142.
18. Knowles H.J., Raval R.R., Harris A.L., Ratcliffe P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 2003, 63(8):1764-1768.
19. Lu H., Dalgard C.L., Mohyeldin A., McFate T., Tait A.S., Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005, 280(51):41928-41939.
20. Pan Y., Mansfield K.D., Bertozzi C.C., et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 2007, 27(3):912-925.
21. McCarty M.F., Barroso-Aranda J., Contreras F. Oxidative stress therapy for solid tumors - a proposal. Med Hypotheses 2010, 74(6):1052-1054.
22. Brar S.S., Kennedy T.P., Quinn M., Hoidal J.R. Redox signaling of NF-kappaB by membrane NAD(P)H oxidases in normal and malignant cells. Protoplasma 2003, 221(1-2):117-127.
23. Chandel N.S., McClintock D.S., Feliciano C.E., et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 2000, 275(33):25130-25138.
24. Schroedl C., McClintock D.S., Budinger G.R., Chandel N.S. Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2002, 283(5):L922-L931.
25. Guzy R.D., Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006, 91(5):807-819.
26. McFate T., Mohyeldin A., Lu H., et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008, 283(33):22700-22708.
27. Selak M.A., Armour S.M., MacKenzie E.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7(1):77-85.
28. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007, 39(3):231-234.
29. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6(3):203-208.
30. McCarty M.F., Block K.I. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Integr Cancer Ther 2006, 5(3):252-268.
31. van U.P., Kenneth N.S., Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008, 412(3):477-484.
32. Carcamo J.M., Pedraza A., Borquez-Ojeda O., Golde D.W. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 2002, 41(43):12995-13002.
33. Suzuki Y.J., Aggarwal B.B., Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem Biophys Res Commun 1992, 189(3):1709-1715.
34. Zhang W.J., Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001, 15(13):2423-2432.
35. Takeuchi J., Hirota K., Itoh T., et al. Thioredoxin inhibits tumor necrosis factor- or interleukin-1-induced NF-kappaB activation at a level upstream of NF-kappaB-inducing kinase. Antioxid Redox Signal 2000, 2(1):83-92.
36. Zhang J., Johnston G., Stebler B., Keller E.T. Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase. Antioxid Redox Signal 2001, 3(3):493-504.
37. Carcamo J.M., Pedraza A., Borquez-Ojeda O., Zhang B., Sanchez R., Golde D.W. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta. Mol Cell Biol 2004, 24(15):6645-6652.
38. Cummins E.P., Berra E., Comerford K.M., et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006, 103(48):18154-18159.
39. Kawada H., Kaneko M., Sawanobori M., et al. High concentrations of l-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1alpha transcription. PLoS One 2013, 8(4):e62717.
40. Liang W.J., Johnson D., Jarvis S.M. Vitamin C transport systems of mammalian cells. Mol Membr Biol 2001, 18(1):87-95.
41. Savini I., Rossi A., Pierro C., Avigliano L., Catani M.V. SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 2008, 34(3):347-355.
42. Corti A., Casini A.F., Pompella A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch Biochem Biophys 2010, 500(2):107-115.
43. Ormazabal V., Zuniga F.A., Escobar E., et al. Histidine residues in the Na+-coupled ascorbic acid transporter-2 (SVCT2) are central regulators of SVCT2 function, modulating pH sensitivity, transporter kinetics, Na+ cooperativity, conformational stability, and subcellular localization. J Biol Chem 2010, 285(47):36471-36485.
44. Creagan E.T., Moertel C.G., O'Fallon J.R., et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979, 301(13):687-690.
45. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985, 312(3):137-141.
46. Kuiper C., Molenaar I.G., Dachs G.U., Currie M.J., Sykes P.H., Vissers M.C. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res 2010, 70(14):5749-5758.
47. Kim J., Yamamoto F., Gondo S., Yanase T., Mukai T., Maeda M. 6-Deoxy-6-[131I]iodo-l-ascorbic acid for the in vivo study of ascorbate: autoradiography, biodistribution in normal and hypolipidemic rats, and in tumor-bearing nude mice. Biol Pharm Bull 2009, 32(11):1906-1911.
48. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49(23):6449-6465.
49. Gillies R.J., Raghunand N., Garcia-Martin M.L., Gatenby R.A. PH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag 2004, 23(5):57-64.
50. Silva A.S., Yunes J.A., Gillies R.J., Gatenby R.A. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res 2009, 69(6):2677-2684.
51. McCarty M.F., Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Altern Med Rev 2010, 15(3):264-272.
52. Xu L., Fukumura D., Jain R.K. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 2002, 277(13):11368-11374.
53. Xu L., Fidler I.J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res 2000, 60(16):4610-4616.
54. Kato Y., Lambert C.A., Colige A.C., et al. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase d-mitogen-activated protein kinase signaling. J Biol Chem 2005, 280(12):10938-10944.
55. Rofstad E.K., Mathiesen B., Kindem K., Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006, 66(13):6699-6707.
56. Martinez-Zaguilan R., Seftor E.A., Seftor R.E., Chu Y.W., Gillies R.J., Hendrix M.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996, 14(2):176-186.
57. Moellering R.E., Black K.C., Krishnamurty C., et al. Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis 2008, 25(4):411-425.
58. Raghunand N., He X., Van S.R., et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999, 80(7):1005-1011.
59. Raghunand N., Mahoney B., Van S.R., Baggett B., Gillies R.J. Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 2001, 3(3):227-235.
60. Robey I.F., Baggett B.K., Kirkpatrick N.D., et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009, 69(6):2260-2268.
61. Luciani F., Spada M., De M.A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004, 96(22):1702-1713.
62. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001, 69(4):522-530.
63. Fischer B., Muller B., Fisch P., Kreutz W. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J Immunother 2000, 23(2):196-207.
64. Fischer K., Hoffmann P., Voelkl S., et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109(9):3812-3819.
65. Gottfried E., Kreutz M., Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008, 19(1):65-77.
66. Airley R.E., Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53(4):233-256.
67. Heaney M.L., Gardner J.R., Karasavvas N., et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008, 68(19):8031-8038.
68. Spielholz C., Golde D.W., Houghton A.N., Nualart F., Vera J.C. Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res 1997, 57(12):2529-2537.
69. Agus D.B., Vera J.C., Golde D.W. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999, 59(18):4555-4558.
70. Corti A., Raggi C., Franzini M., Paolicchi A., Pompella A., Casini A.F. Plasma membrane gamma-glutamyltransferase activity facilitates the uptake of vitamin C in melanoma cells. Free Radical Biol Med 2004, 37(11):1906-1915.
71. Huang J., Agus D.B., Winfree C.J., et al. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci USA 2001, 98(20):11720-11724.
72. De T.V., Brizzi S., Saviozzi M., et al. Protective role of dehydroascorbate in rat liver ischemia-reperfusion injury. J Surg Res 2005, 123(2):215-221.
73. Heise E., Luhrs W., Neunhoeffer O. Effects of dehydroascorbic acid on tumor metabolism. Z Krebsforsch 1958, 62(5):509-515.
74. Yamafuji K., Nakamura Y., Omura H., Soeda T., Gyotoku K. Antitumor potency of ascorbic, dehydroascorbic or 2,3-diketogulonic acid and their action on deoxyribonucleic acid. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1971, 76(1):1-7.
75. Poydock M.E., Reikert D., Rice J., Aleandri L. Inhibiting effect of dehydroascorbic acid on cell division in ascites tumors in mice. Exp Cell Biol 1982, 50(1):34-38.
76. Poydock M.E., Harguindey S., Hart T., Takita H., Kelly D. Mitogenic inhibition and effect on survival of mice bearing L1210 leukemia using a combination of dehydroascorbic acid and hydroxycobalamin. Am J Clin Oncol 1985, 8(3):266-269.
77. Poydock M.E. Effect of combined ascorbic acid and B-12 on survival of mice with implanted Ehrlich carcinoma and L1210 leukemia. Am J Clin Nutr 1991, 54(Suppl. 6):1261S-1265S.
78. Toohey J.I. Dehydroascorbic acid as an anti-cancer agent. Cancer Lett 2008, 263(2):164-169.
79. Gao P., Zhang H., Dinavahi R., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12(3):230-238.
80. McCarty M.F. Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 2007, 10(4):566-570.
81. Manabe E., Handa O., Naito Y., et al. Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem 2008, 103(6):1925-1937.
82. Liu X., Osawa T. Astaxanthin protects neuronal cells against oxidative damage and is a potent candidate for brain food. Forum Nutr 2009, 61:129-135.
83. Liu X., Shibata T., Hisaka S., Osawa T. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res 2009, 1254:18-27.
84. Wolf A.M., Asoh S., Hiranuma H., et al. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J Nutr Biochem 2010, 21(5):381-389.
85. Pashkow F.J., Watumull D.G., Campbell C.L. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008, 101(10A):58D-68D.
86. Curek G.D., Cort A., Yucel G., et al. Effect of astaxanthin on hepatocellular injury following ischemia/reperfusion. Toxicology 2010, 267(1-3):147-153.
87. Stacpoole P.W., Henderson G.N., Yan Z., James M.O. Clinical pharmacology and toxicology of dichloroacetate. Environ Health Perspect 1998, 106(Suppl. 4):989-994.
88. Michelakis E.D., Webster L., Mackey J.R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008, 99(7):989-994.
89. Sun R.C., Fadia M., Dahlstrom J.E., Parish C.R., Board P.G., Blackburn A.C. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2010, 120(1):253-260.
90. Chen Q., Espey M.G., Krishna M.C., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005, 102(38):13604-13609.
91. Chen Q., Espey M.G., Sun A.Y., et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007, 104(21):8749-8754.
92. Chen Q., Espey M.G., Sun A.Y., et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008, 105(32):11105-11109.
93. Espey M.G., Chen P., Chalmers B., et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radical Biol Med 2011, 50(11):1610-1619.
94. Verrax J., Calderon P.B. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radical Biol Med 2009, 47(1):32-40.
95. McCarty M.F., Barroso-Aranda J., Contreras F. A two-phase strategy for treatment of oxidant-dependent cancers. Med Hypotheses 2007, 69(3):489-496.